Trial Profile

Phase 3 randomized study of CRDF005

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRDF 005 (Primary)
Indications Unspecified
Focus Registrational; Therapeutic Use
Sponsors Cardiff Oncology

Most Recent Events

04 Mar 2024 New trial record
29 Feb 2024 According to Cardiff Oncology media release, the company will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
29 Feb 2024 According to a Cardiff Oncology media release, the company will initiate a Phase 3, randomized trial, CRDF005, with registrational intent.The FDA has agreed that ORR at an interim point is an acceptable endpoint to pursue accelerated approval of onvansertib from the CRDF-005 trial, with PFS and trend in overall survival being the endpoints for full approval.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com